- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly's Alzheimer's gamble takes aim at $10 billion in patent losses
July 13, 2010
Bloomberg NewsBoth of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
MoreLilly to cut 170 manufacturing jobs by year's end
July 12, 2010
J.K. WallEli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the
end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling
drugs.
MoreDiagnostics division to help Lilly tailor treatments
July 10, 2010
J.K. WallEli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit
from a Lilly drug.
MoreLilly's Lechleiter: No change in plans
July 7, 2010
J.K. WallThe global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
MoreMen on Viagra, Cialis show triple rate of sex diseases in study
July 6, 2010
IBJ Staff and Bloomberg NewsThe findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly's Cialis, may be more likely to
engage in unsafe sex than nonusers.
MoreLilly acquires biotech company with pancreatic drug
July 2, 2010
J.K. WallMassachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.
MoreGrassley asks Lilly, peers about whistleblower treatment
July 1, 2010
Bloomberg NewsU.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal
how they treat whistleblowers who file complaints under the False Claims Act.
MoreLilly's Effient steps forward, then back
June 30, 2010
J.K. WallA day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor,
Plavix,
a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
MoreMarcadia enlists Lilly to help develop new diabetes drug
June 28, 2010
J.K. WallThe two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
MoreHoosier firms that rely on innovation pine for patent reform
June 26, 2010
J.K. WallOne key change would grant patents to the first inventor to file an application, not the first who can prove to have made
the invention first.
MoreLilly layoffs pare communications department
June 21, 2010
J.K. WallThe giant drugmaker is in the process of trimming 35 percent—or about 19 people—from its 55-person communications
staff. Most of that staff is based in Indianapolis.
MoreRecession hammered revenue of Indiana's largest public companies
June 19, 2010
Marc D. AllanFew escaped the Great Recession unscathed, and unusual circumstances helped some appear as though they did.
MoreSlow economy bruises profits of Indiana's largest public companies
June 19, 2010
Marc D. AllanOne-time events influenced bottom lines of some of the few companies that made more money in 2009.
MoreLilly, Amylin stock rises on drug postponement
June 18, 2010
IBJ Staff and Bloomberg NewsRoche Holding AG's decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
MoreResearch reforms will force Lilly, others to test how drugs stack up
June 12, 2010
J.K. WallThe federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical
treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness
research could threaten their sales.
MoreLilly taps O'Connor as state lobbyist
June 9, 2010
J.K. WallO’Connor, chief deputy mayor under former Indianapolis Mayor Bart Peterson, started Monday as Lilly's director of
state government affairs—working again under Peterson.
MoreErbitux fails to stop colon cancer before it spreads
June 6, 2010
Bloomberg NewsEli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine's use to patients whose
disease is in an earlier stage.
MoreGenetic testing could spur Erbitux drug sales
June 1, 2010
Bloomberg NewsThe drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
MoreLilly grows Alimta's sales by shrinking market
May 29, 2010
J.K. WallIn 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment
for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales
of the drug have accelerated, growing a whopping 48 percent last year.
MoreIndianapolis startup attacks Alzheimer's disease
May 29, 2010
Norm HeikensAgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual
property, and begin learning how to make a drug into a once-a-day pill.
MoreEli Lilly invests in $250M Australian venture fund
May 20, 2010
IBJ Staff and Bloomberg NewsThe unnamed venture fund will be based in Brisbane, and will focus on biotechnology investments in Australia and southeastern
Asia.
MoreDrug-spending increase highest in four years
May 20, 2010
Bloomberg NewsThe price increase was fueled by the debate over the health-care overhaul in Washington, D.C., Medco Health Solutions Inc.
CEO David Snow said.
MoreLilly, others cut U.S. tax bills through transfer pricing
May 14, 2010
Bloomberg NewsU.S. companies, including Eli Lilly, amassed at least $1 trillion in foreign profits not taxed in the U.S. as of the end of
last year. That cumulative total increased 70 percent over three years.
MoreLilly still waiting on once-weekly Byetta
May 12, 2010
J.K. WallThe U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the
drug Bydureon to Oct. 22. The previous deadline was in March.
MoreLilly hopes Elanco unit becomes a cash cow
May 8, 2010
J.K. WallElanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco's productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Saw the Indy Men's Chorus "Music of Gilbert & Sullivan" at the Indiana Historical Society on Sunday evening.
Temporary workers are not "tools" they are people and companies that keep large amounts of temp staff are cheating.
I miss having them around. I hope one of their stores is in the general Meridian/86th Street area. I will make good use of it.
The Fringe! Plus, the simple fact that there are so many local faves in such close proximity to each other.
I remenber, watching the toll road, being built, through South Bend, when I was 10 years old. I believe, back then that it was estimated, that the toll road, would be paid for in 20 years and then it would be free. I am now 71, what happened? Since the power is in the people, by that, I mean that, we the people are in total control of everything. I, suggest that no one ever use the toll road again, let it go broke. We the people can control the price of everything, from groceries to gas, if we would just do it. If we don't pay the asking price, the sellers will lower the price and if we wait awhile, they will lower the price to what we accept as reasonable. I would like to know why a highway like interstate 94, is so well maintained, a much better highway, than the toll road, but has no tolls. I would also like to know why, a sitting governor, with a term limit, maximum of eight years, can lease, public property, for 75 years. Even though I have transponders in both of my trucks and will not be affected by the increase, I have been and will contine to avoid using the toll road. I make many trips from northern Indiana to Chicago, every year, and I prefer the better highway, I94!